Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | THRB | P10828 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5871823 | 0.94 | MAPT (0.42) | MAPTTHRBPTGDR2L3MBTL1ALDH1A1 | |
| SCHEMBL5871627 | 0.91 | MAPT (0.40) | MAPTTHRBTP53RXFP1L3MBTL1 | |
| SCHEMBL7955076 | 0.84 | LIPG (0.42) | MAPTTHRBRXFP1L3MBTL1ALDH1A1 | |
| SCHEMBL5872271 | 0.84 | MAPT (0.41) | MAPTTHRBPTGDR2L3MBTL1ALDH1A1 | |
| SCHEMBL5871382 | 0.82 | LIPG (0.37) | THRBL3MBTL1 | |
| SCHEMBL7955057 | 0.76 | PDE4A (0.51) | MAPTTHRBTP53PTGDR2RXFP1 | |
| SCHEMBL7954712 | 0.74 | PDE4A (0.48) | MAPTTHRBTP53PTGDR2RXFP1 | |
| SCHEMBL5872204 | 0.69 | MAPT (0.53) | MAPTTHRBTP53PTGDR2RXFP1 | |
| SCHEMBL5871439 | 0.69 | LIPG (0.43) | MAPTTHRBRXFP1L3MBTL1ALDH1A1 | |
| SCHEMBL7954380 | 0.68 | RXFP1 (0.52) | MAPTTHRBTP53PTGDR2RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071187-B2 | Naphthyridine derivatives | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2006-07-04 | — | — | US | claimed |
| US-20040214853-A1 | Naphthyridine derivatives | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2004-10-28 | — | — | US | claimed |
| EP-1426374-A1 | NAPHTHYRIDINE DERIVATIVE | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2004-06-09 | — | — | EP | claimed |
| US-7071187-B2 | Naphthyridine derivatives | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2006-07-04 | — | — | US | disclosed |
| US-20040214853-A1 | Naphthyridine derivatives | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2004-10-28 | — | — | US | disclosed |
| EP-1426374-A1 | NAPHTHYRIDINE DERIVATIVE | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2004-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214853-A1 | Naphthyridine derivatives | MT-ND1, OPRD1, NR0B1 | MAPT 2184/4885THRB 3266/4885TP53 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.